血浆氧化三甲胺预测1型糖尿病心肾并发症的价值
在1159例1型糖尿病患者中,基线血浆TMAO升高与全因死亡、心血管死亡、心血管事件及肾脏事件相关,且独立于传统心血管危险因素;但进一步校正基线eGFR后关联均不显著,TMAO与eGFR呈负相关(R²=0.29)。
要点
- TMAO升高与1型糖尿病全因死亡、心血管事件和肾脏事件相关。
- 校正传统危险因素后关联仍显著,但校正基线eGFR后消失。
- TMAO可能反映肾功能或经肾功能损害介导并发症风险。
核心结论
- 在1型糖尿病患者中,较高血浆TMAO浓度与死亡、心血管事件和不良肾脏结局相关,且独立于传统危险因素。
- 但进一步校正基线eGFR后关联变得不显著,提示TMAO可能反映肾功能或经肾功能损害介导微血管和大血管并发症风险。
研究设计与样本
- 前瞻性研究,纳入1159例1型糖尿病患者(58%男性,平均年龄46±13岁),基线测量血浆TMAO。
- 终点包括全因死亡、心血管死亡、心血管疾病、肾脏事件,通过国家登记系统追踪。
- 采用Cox回归模型检验TMAO与终点的关联。
主要发现
- 中位随访15.0(6.7-19.3)年,记录全因死亡363例、心血管死亡120例、复合心血管疾病406例、冠脉结局163例、卒中115例、心衰住院81例、终末期肾病144例。
- 单变量分析中,较高TMAO浓度与所有终点相关(P≤0.005)。
- 除卒中和心衰外,校正传统心血管危险因素后,所有终点仍与较高TMAO浓度显著相关(P≤0.003)。
- 进一步校正基线eGFR后,所有终点关联均不显著。
- TMAO与基线eGFR呈负相关(R²=0.29;P<0.001)。
临床怎么用
- TMAO不宜单独作为1型糖尿病心肾并发症的独立预测指标,解读时应结合eGFR。
- TMAO与eGFR的负相关提示其可能作为肾功能标志物,而非独立致病因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Trimethylamine N-oxide (TMAO) is suggested as an independent gut microbiota-derived risk factor for cardiovascular and renal disease. We investigated associations between plasma TMAO concentrations and cardio-renal outcomes in a prospective study of individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Plasma TMAO was measured at baseline in 1,159 individuals with type 1 diabetes (58% male, mean ± SD age 46 ± 13 years). End points were all-cause and cardiovascular mortality, cardiovascular disease (CVD), and renal events tracked from national registries. Associations between TMAO and end points were tested using Cox regression models. RESULTS: After 15.0 (6.7-19.3) (median [interquartile range]) years of follow-up, we recorded all-cause and cardiovascular mortality (n = 363 and 120, respectively), combined CVD (n = 406), coronary outcome (myocardial infarction and coronary intervention) (n = 163), stroke (n = 115), hospitalization for heart failure (n = 81), and end-stage renal disease (n = 144). In univariate analyses, higher TMAO concentrations were associated with all end points (P ≤ 0.005). Except for stroke and heart failure, all end points remained significantly associated with higher TMAO concentrations after adjustment for conventional cardiovascular risk factors (P ≤ 0.003). After further adjustment for baseline estimated glomerular filtration rate (eGFR), results became insignificant for all end points. TMAO was inversely associated with baseline eGFR (R 2 = 0.29; P < 0.001). CONCLUSIONS: In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors. However, the association became insignificant after further adjustment for baseline eGFR. This could reflect TMAO as a renal function marker or a risk factor for micro- and macrovascular complications mediated through impaired renal function.
引用
- Winther SA, Øllgaard JC, Tofte N, et al. Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care. 2019. PMID: 31123156. doi:10.2337/dc19-0048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。